Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trials for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 3 9826 0399
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$240,109.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Opthea (ASX:OPT) Frequently Asked Questions
What is Opthea's stock symbol?
Opthea trades on the ASX under the ticker symbol "OPT."
How were Opthea's earnings last quarter?
Opthea Ltd (ASX:OPT) issued its earnings results on Friday, August, 9th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.00. View Opthea's Earnings History.
Has Opthea been receiving favorable news coverage?
Press coverage about OPT stock has trended extremely negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Opthea earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Opthea.
Who are some of Opthea's key competitors?
Some companies that are related to Opthea include Dechra Pharmaceuticals (DPH), Hutchison China MediTech (HCM), Medical Developments International (MVP), Mayne Pharma Group (MYX), Vectura Group (VEC), BEXIMCO PHARMAC/S GDR REGS (BXP), Eco Animal Health Group (EAH), Trilogy International Partners (TRL), Allergy Therapeutics (AGY), Recce Pharmaceuticals (RCE), NanoViricides (NNVC), Pharmaxis (PXS), Vita Life Sciences (VLS), Futura Medical (FUM) and Avivagen (VIV).
Who are Opthea's key executives?
Opthea's management team includes the folowing people:
- Dr. Megan Baldwin Ph.D., MAICD, MD, CEO & Exec. Director
- Mr. Michael Tonroe, CFO & Company Sec.
- Mr. Richard Chadwick Ph.D., Head of Intellectual Property
- Dr. Michael Gerometta, Head of CMC Devel.
- Dr. Ian Leitch, Director of Clinical Research
What is Opthea's stock price today?
One share of OPT stock can currently be purchased for approximately A$3.36.
How big of a company is Opthea?
What is Opthea's official website?
How can I contact Opthea?
The company can be reached via phone at 61 3 9826 0399.
MarketBeat Community Rating for Opthea (ASX OPT)
MarketBeat's community ratings are surveys of what our community members think about Opthea and other stocks. Vote "Outperform" if you believe OPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
